Open AccessBone flare after initiation of novel hormonal therapy in patients with metastatic hormone-sensitive prostate cancer: A case report
Author(s) -
Ke-Hao Li,
Ying Du,
Dongyu Yang,
Xin-Yuan Yu,
Xueping Zhang,
Yongxiang Li,
Liang Qiao
Publication year - 2022
Publication title -
world journal of clinical cases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.368
H-Index - 10
ISSN - 2307-8960
DOI - 10.12998/wjcc.v10.i15.4985
Subject(s) - medicine , prostate cancer , hormonal therapy , androgen deprivation therapy , enzalutamide , prostate , bone metastasis , radionuclide therapy , urology , oncology , cancer , radiology , androgen receptor
The 2020 European Association of Urology prostate cancer guidelines recommend androgen deprivation therapy (ADT) in combination with apalutamide and enzalutamide, a new generation of androgen receptor antagonists, as first-line therapy. A decrease in prostate-specific antigen (PSA) levels may occur in the early stages of novel hormonal therapy; however, radionuclide bone imaging may suggest disease progression. During follow-up, PSA, radionuclide bone imaging, and prostate-specific membrane antigen (PSMA) positron emission tomography - computed tomography (PET-CT) are needed for systematic evaluation.